Vergoeding 2019-2023 voor ATC-subgroep H01CB : Somatostatine en analogen
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| H01CB02 Octreotide (Sandostatine ®) | 22.726.900 | 21.130.800 | 15.103.300 | 14.497.400 | 14.437.500 |
| H01CB03 Lanreotide (Somatuline ®) | 23.342.800 | 25.080.900 | 22.420.300 | 21.805.900 | 18.716.300 |
| H01CB05 Pasireotide (Signifor ®) | 2.429.600 | 2.433.800 | 2.262.300 | 2.366.300 | 2.388.700 |
| Totaal | 48.499.300 | 48.645.500 | 39.785.900 | 38.669.600 | 35.542.500 |